PMS45 Cost-Utility and Budget Impact Analysis of Certolizumab Pegol Plus Methotrexate for the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis in Greece
Abstract
Authors
N. Maniadakis D. Boumpas G. Kourlaba P. Christou I. Anargiros E. Smets O Purcaru